Unverified50% confidenceFactExact time
Antibody developability is a comprehensive indicator for evaluating whether a candidate antibody can become a drug, covering target affinity, thermal stability, aggregation propensity, expression yield, immunogenicity and half-life.
1
Sources
50%
Confidence
Long-term
Relevance
10/29/2026
First Seen
Sources
Related Entities
Related Claims
UnverifiedAntibody design is an inverse problem: given a target structure, reverse-engineer an antibody sequence capable of binding to it.68% similarUnverifiedCurrent mainstream AI antibody design methods include structure generation based on diffusion models (such as RFdiffusion), sequence generation based on language models (such as ESM and AntiBERTy), and hybrid architectures.64% similarVerifiedThe application of artificial intelligence in protein structure prediction, target screening, and clinical trial design is compressing the drug development cycle.63% similarUnverifiedVerifiability is the core variable that determines whether a given discipline can be among the first to benefit from AI breakthroughs.59% similarUnverifiedAssessing AI's actual contribution in drug R&D typically uses the number of candidate molecules entering clinical trials and the clinical success rate as interim metrics.59% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1112745API
curl https://kongchang.com/api/v1/knowledge/claims/1112745MCP
get_claim(id=1112745)